Molecular Mechanism of P53 Peptide Permeation through Lipid Membranes from Solid-State NMR Spectroscopy and Molecular Dynamics Simulations-Reference-Cited by-同舟云学术

Molecular Mechanism of P53 Peptide Permeation through Lipid Membranes from Solid-State NMR Spectroscopy and Molecular Dynamics Simulations

Published:2024-08-07 Issue:33 Volume:146 Page:23075-23091
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Li Mingyue¹,Li Jianguo²³^ORCID,Lu Xingyu¹⁴,Schroder Ryan¹,Chandramohan Arun⁵,Wuelfing W. Peter¹^ORCID,Templeton Allen C.¹,Xu Wei¹,Gindy Marian⁶,Kesisoglou Filippos¹,Ling Jing¹,Sawyer Tomi⁷,Verma Chandra S.²⁸⁹^ORCID,Partridge Anthony W.⁵,Su Yongchao¹^ORCID

Affiliation:

1. Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, New Jersey 07065, United States

2. Bioinformatics Institute at A*STAR (Agency for Science, Technology and Research), 30 Biopolis Street, #07-01 Matrix, Singapore 138671, Singapore

3. Singapore Eye Research Institute, 20 College Road Discovery Tower, Singapore 169856, Singapore

4. Instrumentation and Service Center for Molecular Sciences, Westlake University, Hangzhou, Zhejiang 310024, China

5. Quantitative Biosciences, MSD, Singapore 138665, Singapore

6. Small Molecule Science and Technology, Merck & Co., Inc., Rahway, New Jersey 07065, United States

7. Merck & Co., Inc., Boston, Massachusetts 02115, United States

8. Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117543, Singapore

9. School of Biological Sciences, Nanyang Technological University, 50 Nanyang Drive, Singapore 637551, Singapore

Funder

Agency for Science, Technology and Research

Merck

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/jacs.4c04230

Reference102 articles.

1. The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members

2. Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges

3. Therapeutic peptides: Historical perspectives, current development trends, and future directions

4. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

5. Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye